A Kerala doctor is making ground breaking strides towards revolutionising cancer treatment by utilising the discovery of “attack particles,” a powerful suite of weapons in the immune system’s arsenal that can fight diseases such as cancers, autoimmunity and infections.
Dr. Ashwin Nandakumar of Kochi, along with Dr. Ashwin Jainarayanan of Chennai and Prof. Michael Dustin of Oxford, has embarked on an innovative journey to combat cancer by pioneering their research on “attack particles”.
Granza Bio, the biotechnology startup founded by the trio, who are cancer and immunology researchers at the University of Oxford, has recently secured over US $7.14 million in seed funding to advance the delivery of their cancer treatment. The substantial investment will enable the team to accelerate their research, conduct clinical trials, and move closer to bringing their innovative therapeutics to market.
The investment was made by Felicis and Refactor, along with Y Combinator and other notable angel investors.
“We are developing a series of precision delivery shells that can encompass and direct any therapeutic cargo to the correct destination in our body. This work will be fundamental for turning promising discoveries in genetic medicine and cancer therapeutics into impactful treatments for patients,” Granza co-founder and Chief Executive Officer Dr. Ashwin Nandakumar was quoted as saying in an official release announcing the seed fund investment. The trio has been developing cutting-edge cancer therapeutics focusing on harnessing the power of attack particles, which can target and eradicate cancer cells.
Dr Nandakumar holds a PhD in Oncology and has been working on early-stage cancer prevention strategies for the last few years.
